173997-05-2

Basic information

• Product Name: Nepicastat
• Synonyms: Nepicastat;Nepicastat [inn];5-(AMinoMethyl)-1-((S)-5,7-difluoro-1,2,3,4-tetrahydro-2-naphthyl)-4-iMidazoline-2-thione;5-(Aminomethyl)-1-[(2S)-5,7-difluoro-1,2,3,4-tetrahydro-2-naphthalenyl]-1,3-dihydro-2H-imidazole-2-thione;RS-25560-197;SYN117;Nepicastat (free base) (SYN-117);Nepicastat HCl
• CAS NO: 173997-05-2
• Molecular Formula: C14H15F2N3S
• Molecular Weight: 295.3508064
• Product Categories: API
• Mol File: 173997-05-2.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 401.832 °C at 760 mmHg
• Flash Point: 196.821 °C
• Appearance: /
• Density: 1.40
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.665
• CAS DataBase Reference: Nepicastat(CAS DataBase Reference)
• NIST Chemistry Reference: Nepicastat(173997-05-2)
• EPA Substance Registry System: Nepicastat(173997-05-2)

Safety Data

• Hazardous Substances Data: 173997-05-2(Hazardous Substances Data)

Usage

Uses

Treatment of congestive heart failure (dopamine β-hydroxylase inhibitor).

InChI:InChI=1/C14H15F2N3S/c15-9-3-8-4-10(1-2-12(8)13(16)5-9)19-11(6-17)7-18-14(19)20/h3,5,7,10H,1-2,4,6,17H2,(H,18,20)/t10-/m0/s1

Upstream product

• 304-59-6 Rochelle's salt 

Relevant articles and documents

METHODS FOR TREATING DEPENDENCE

no abstract published

Benzocycloalkylazolethione derivatives

The present invention relates to novel benzocycloalkylazolethione compounds which are dopamine β-hydroxylase inhibitors in which the benzocycloalkyl portion of the compound is selected from indanyl, 1,2,3,4-tetrahydronaphthalenyl and 6,7,8,9-tetrahydro-5H-benzocycloheptenyl (in which the benzo is optionally substituted with one to three substituents) and the azolethione portion of the compound is selected from 2-thioxo-2,3-dihydro-1H-imidazol-3-yl, 5-thioxo-4,5-dihydro-1H-[1,2,4]triazol-4-yl and 5-thioxo-4,5-dihydro-1H-[1,2,4]triazol-1-yl (each optionally substituted with one to three substituents); and the prodrugs, pharmaceutically acceptable salts, individual isomers and mixtures of isomers and the methods of using and preparing such benzocycloalkylazolethione compounds.